文献速递脑血管病

DEFUSE 3 研究中超过 24 小时持续目标不匹配特征

Persistent Target Mismatch Profile >24 Hours After Stroke Onset in DEFUSE 3.
PubMed 文献 · Stroke · 2019-01-01

这些患者基线低灌注强度比更低,梗死增长更少,但 90 天良好临床结局仅 10%。

要点

  • 约 20% 延长时间窗未取栓的大血管闭塞患者存在持续不匹配至少额外 24 小时。
  • 持续有利灌注特征者基线低灌注强度比更低(0.2 对 0.4,P<0.01),提示侧支循环良好。
  • 此类患者 24 小时梗死体积更小(15 对 59 mL,P<0.001),但 90 天良好结局仅 10%。

核心结论

  • 约 20% 延长时间窗内未接受取栓的大脑中动脉或颈内动脉闭塞患者存在持续不匹配至少额外 24 小时。
  • 这些患者基线低灌注强度比有利,可能发生延迟性梗死扩大,且临床结局较差。

研究设计与样本

  • 研究为 DEFUSE 3 试验对照组的回顾性分析,纳入随机化 24 小时后完成弥散加权成像和灌注磁共振成像的患者。
  • 比较持续不匹配患者与 24 小时后不再有不匹配患者的影像和临床变量。

主要发现

  • 持续不匹配患者与初始有利灌注转为不利的患者基线 DWI 病变体积(7 对 17 mL,P=0.17)和 Tmax >6 秒体积(98 对 100 mL,P=0.48)相似。
  • 持续不匹配患者随机化 24 小时后梗死增长更少(15 对 59 mL,P<0.001),梗死体积小 3 倍(15 对 59 mL,P<0.001)。
  • 持续有利灌注特征患者基线低灌注强度比显著更低(0.2 对 0.4,P<0.01)。
  • 持续不匹配患者 90 天良好临床结局仅占 10%。

关键数值与推荐

  • 持续有利灌注特征定义为最后已知良好时间超过 38 小时后仍存在目标不匹配。
  • 基线低灌注强度比 0.2 对 0.4(P<0.01)与持续有利灌注特征相关。

临床怎么用

  • 对于延长时间窗内大血管闭塞患者,基线低灌注强度比低可能提示持续不匹配和延迟梗死扩大。
  • 此类患者即使超过 24 小时仍可能从再灌注治疗中获益,需临床试验验证。

局限性

  • 研究仅分析 DEFUSE 3 试验对照组患者,样本量有限。
  • 持续不匹配患者 90 天良好结局仅 10%,需进一步探讨再灌注获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Efficacy of endovascular thrombectomy has been demonstrated up to 24 hours after stroke onset in patients selected with perfusion imaging. We hypothesized that a persistent favorable perfusion profile exists in some patients beyond 24 hours from the onset and can be predicted by a lower baseline hypoperfusion intensity ratio, which indicates favorable collaterals. Methods- We identified control arm patients from the DEFUSE 3 trial (The Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke) with a diffusion weighted imaging and perfusion magnetic resonance imaging performed 24 hours following randomization and compared imaging and clinical variables between patients with persistent mismatch versus patients who no longer had a mismatch 24 hours after randomization. Results- Eighteen percent of the control arm patients had a persistent favorable profile >38 hours after last known well time. These patients had similar baseline diffusion weighted imaging and Tmax >6 seconds volumes as patients whose initially favorable perfusion profile became unfavorable (diffusion weighted imaging lesion 7 versus 17 mL; P=0.17, Tmax >6 seconds 98 versus 100 mL; P=0.48) yet experienced less infarct growth (15 versus 59 mL; P<0.001) and had 3-fold smaller infarct volumes (15 versus 59 mL; P<0.001) 24 hours after randomization. Patients with a persistent favorable perfusion profile had a significantly lower hypoperfusion intensity ratio on baseline imaging (0.2 versus 0.4; P<0.01). Favorable clinical outcome at 90 days occurred in only 10% of the persistent mismatch patients. Conclusions- About 20% of patients with a middle cerebral artery or internal carotid artery occlusion who present in an extended time window and are not treated with thrombectomy have a persistent mismatch for at least an additional 24 hours. These patients have a favorable hypoperfusion intensity ratio at presentation, may experience delayed infarct expansion, and have poor clinical outcomes. Clinical trials are needed to determine if patients with a favorable perfusion profile benefit from reperfusion beyond 24 hours. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02586415.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Christensen S, Mlynash M, Kemp S, et al. Persistent Target Mismatch Profile >24 Hours After Stroke Onset in DEFUSE 3. Stroke. 2019. PMID: 30735466. doi:10.1161/STROKEAHA.118.023392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。